Rock Springs Capital's book
16 companies · priced by our data| Company | Industry | Valuation | $/share | First invested | Role |
|---|---|---|---|---|---|
| Freenome | Decision/Risk Analysis | $2.2B | — | — | |
| ArsenalBio | — | $1.9B | — | — | |
| Imperative Care | Surgical Devices | $1.6B | — | — | |
| Treeline Biosciences | — | $1.3B | — | — | |
| Caidya | Other Healthcare Services | $1.0B | — | — | |
| Parabilis Medicines | Drug Discovery | $920.0M | — | — | |
| Delfi Diagnostics | — | $725.0M | — | — | |
| Latigo Bio | — | $530.0M | — | — | |
| Synthekine | — | $500.0M | — | — | |
| Hemab Therapeutics Holdings | Drug Discovery | $386.9M | — | — | |
| + 6 more companies · a free account shows the top 25 | |||||
Free account
See the whole book
- ·The book's top 25 — of 16 recorded positions
- ·Watchlist + alerts for Rock Springs Capital's activity
Create free account
No card required